The Leader In Minimally Invasive Denervation Procedures​

Ultra-Sound ablation energy for:

  • Renal Denervation for Hypertension (RDN)
  • Pulmonary Artery Hypertension (PAH)

  • Chronic Obstructive Pulmonary Disease (COPD)

TIVUS - Therapeutic IntraVascular UltraSound

TIVUS is an investigational intravascular device designed for Renal Denervation procedures to treat patients suffering from Hypertension. Early clinical studies have shown that TIVUS can reduce blood pressure in patients suffering from uncontrolled Hypertension.

Latest News

Market Opportunity

There are over 10,000 new PAH cases every year, accounting for a $5 billion drug market. More than 75% of those with PAH are female. We expect the market in the US, EU and Japan to rise to $250-300 million 2027. If TIVUS can work in other subgroups of pulmonary hypertension, such as Group 2, the largest subgroup, the market opportunity is more than $1 billion.

REFERENCES:

  1. Hurdman, J et al 2012.  European Respiratory Journal, 39(4), 945-955.